Regencell Bioscience (NASDAQ:RGC) Trading Down 9.5% – Should You Sell?

Regencell Bioscience Holdings Limited (NASDAQ:RGC) dropped 9.5% during trading on Monday . The company traded as low as $14.50 and last traded at $15.07. Approximately 67,410 shares changed hands during mid-day trading, a decline of 99% from the average daily volume of 8,557,039 shares. The stock had previously closed at $16.65.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Regencell Bioscience in a research report on Saturday, September 27th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, Regencell Bioscience presently has a consensus rating of “Sell”.

Regencell Bioscience Trading Down 10.4%

The firm’s 50-day moving average is $15.62.

Hedge Funds Weigh In On Regencell Bioscience

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Squarepoint Ops LLC bought a new position in Regencell Bioscience in the 2nd quarter worth $1,701,000. BNP Paribas Financial Markets purchased a new position in shares of Regencell Bioscience during the second quarter valued at approximately $768,000. Geode Capital Management LLC grew its stake in shares of Regencell Bioscience by 5,637.5% in the 2nd quarter. Geode Capital Management LLC now owns 391,066 shares of the company’s stock worth $6,664,000 after buying an additional 384,250 shares during the last quarter. Y Intercept Hong Kong Ltd purchased a new position in shares of Regencell Bioscience in the 2nd quarter worth about $222,000. Finally, Greenfield Savings Bank purchased a new stake in Regencell Bioscience during the 2nd quarter valued at about $187,000. 0.13% of the stock is currently owned by institutional investors.

Regencell Bioscience Company Profile

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder.